Charles River Laboratories International, Inc. (NYSE: CRL)
Charles River Laboratories, a leading contract research organization (CRO), has come under positive scrutiny recently. Morgan Stanley upgraded the stock from Equalweight to Overweight, raising the price target from $185 to $220. This optimism is fueled by a surge in biopharma funding, which is expected to boost the company’s proposals and bookings.
Key Highlights:
- Strong Demand: The firm expects the company to benefit from its established preclinical capabilities as biopharma funding grows.
- Earnings Estimates: Morgan Stanley has adjusted its 2027 earnings per share estimates upward by low single digits, anticipating increased safety testing.
- Regulatory Environment: CLSA also upgraded CRL to Outperform, citing a more favorable regulatory climate in China.
Investment Considerations:
While CRL shows promise, there are suggestions that other AI stocks may provide better upside potential with less risk.
For more insights into potentially undervalued stocks, you can explore further reports on specific sectors.
Read Next:
Disclosure: None.
